β3-Adrenergic receptor antagonist improves exercise performance in pacing-induced heart failure

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 305, Issue 6, 2013, Pages

  Masutani, Satoshi ^a   Cheng, Heng Jie ^a   Morimoto, Atsushi ^a   Hasegawa, Hiroshi ^a   Han, Qing Hua ^a   Little, William C ^a   Cheng, Che Ping ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

adrenergic receptor blockers; Congestive heart failure; Pressure volume relation

Indexed keywords

BETA 3 ADRENERGIC RECEPTOR BLOCKING AGENT; L 748337; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EXERCISE; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART PACING; HEART RATE; NONHUMAN; PRIORITY JOURNAL;

Β-ADRENERGIC RECEPTOR BLOCKERS; CONGESTIVE HEART FAILURE; PRESSURE-VOLUME RELATION;

ADRENERGIC BETA-3 RECEPTOR ANTAGONISTS; ANIMALS; DOGS; EXERCISE TEST; EXERCISE TOLERANCE; HEART FAILURE; PHYSICAL EXERTION; RECEPTORS, ADRENERGIC, BETA-3; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84884408109     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00371.2012     Document Type: Article

References (67)

1. Alusik S, Jedickova V, Paluch Z, Zecova S. Plasma levels of nitrite/ nitrate and inflammation markers in elderly individuals. Bratisl Lek Listy 109: 289-292, 2008.
2. Audigane L, Kerfant BG, El Harchi A, Lorenzen-Schmidt I, Toumaniantz G, Cantereau A, Potreau D, Charpentier F, Noireaud J, Gauthier C. Rabbit, a relevant model for the study of cardiac beta3-adrenoceptors. Exp Physiol 94: 400-411, 2009.
3. Beta-Blocker. Evaluation of Survival Trial (B-BEoST) Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344: 1659-1667, 2001.
4. Bianchi P, Kunduzova O, Masini E, Cambon C, Bani D, Raimondi L, Seguelas MH, Nistri S, Colucci W, Leducq N, Parini A. Oxidative stress by monoamine oxidase mediates receptor-independent cardiomyocyte apoptosis by serotonin and postischemic myocardial injury. Circulation 112: 3297-3305, 2005.
5. Borlaug BA, Kass DA. Ventricular-vascular interaction in heart failure. Cardiol Clin 29: 447-459, 2011.
6. Bozkurt B, Bolos M, Deswal A, Ather S, Chan W, Mann DL, Carabello B. New insights into mechanisms of action of carvedilol treatment in chronic heart failure patients-a matter of time for contractility. J Card Fail 18: 183-193, 2012.
7. Bristow MR. [beta]-Adrenergic receptor blockade in chronic heart failure. Circulation 101: 558-569, 2000.
8. Brixius K, Bloch W, Pott C, Napp A, Krahwinkel A, Ziskoven C, Koriller M, Mehlhorn U, Hescheler J, Fleischmann B, Schwinger RH. Mechanisms of beta 3-adrenoceptor-induced eNOS activation in right atrial and left ventricular human myocardium. Br J Pharmacol 143: 1014-1022, 2004.
9. 3-adrenergic receptor antagonists. J Pharmacol Exp Ther 290: 649-655, 1999.
10. Cheng CP, Igarashi Y, Little WC. Mechanism of augmented rate of left ventricular filling during exercise. Circ Res 70: 9-19, 1992.
11. Cheng CP, Noda T, Nozawa T, Little WC. Effect of heart failure on the mechanism of exercise-induced augmentation of mitral valve flow. Circ Res 72: 795-806, 1993.
12. Cheng CP, Suzuki M, Ohte N, Ohno M, Wang ZM, Little WC. Altered ventricular and myocyte response to angiotensin II in pacing-induced heart failure. Circ Res 78: 880-892, 1996.
13. Cheng CP, Ukai T, Onishi K, Ohte N, Suzuki M, Zhang ZS, Cheng HJ, Tachibana H, Igawa A, Little WC. The role of ANG II and endothelin-1 in exercise-induced diastolic dysfunction in heart failure. Am J Physiol Heart Circ Physiol 280: H1853-H1860, 2001.
14. 3-adrenergic receptor in the failing canine myocardium. Circ Res 89: 599-606, 2001.
15. Conraads VM, Metra M, Kamp O, De Keulenaer GW, Pieske B, Zamorano J, Vardas PE, Bohm M, Dei Cas L. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail 14: 219-225, 2012.
16. Conraads VM, Van Craenenbroeck EM, De Maeyer C, Van Berendoncks AM, Beckers PJ, Vrints CJ. Unraveling new mechanisms of exercise intolerance in chronic heart failure. Role of exercise training. Heart Fail Rev 18: 65-77, 2013.
17. 3-adrenoreceptors in rat hearts. Diabetes 50: 455-461, 2001.
18. Ferrari R, Anand IS, Ceconi C, De Giuli F, Poole-Wilson PA, Harris P. Neuroendocrine response to standing and mild exercise in patients with untreated severe congestive heart failure and chronic constrictive pericarditis. Heart 76: 50-55, 1996.
19. Gan RT, Li WM, Xiu CH, Shen JX, Wang X, Wu S, Kong YH. Chronic blocking of beta3-adrenoceptor ameliorates cardiac function in rat model of heart failure. Chin Med J 120: 2250-2255, 2007.
20. 3-adrenoceptors in the cardiovascular system. Trends Pharmacol Sci 21: 426-431, 2000.
21. 3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Invest 102: 1377-1384, 1998.
22. 3-adrenoceptors. Can J Physiol Pharmacol 78: 681-690, 2000.
23. 3 adrenoceptor agonists. J Pharmacol Exp Ther 290: 687-693, 1999.
24. Gilbert JC, Glantz SA. Determinants of left ventricular filling and of the diastolic pressure-volume relations. Circ Res 64: 827-852, 1989.
25. 3-adrenoceptor antagonist SR59230A attenuates the imbalance of systemic and myocardial oxygen transport induced by dopamine in newborn lambs. Clin Med Insights Cardiol 6: 45-51, 2012.
26. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN. Comparative pharmacology at human beta-adrenergic receptor subtypes-characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 369: 151-159, 2004.
27. Izawa H, Yokota M, Takeichi Y, Inagaki M, Nagata K, Iwase M, Sobue T. Adrenergic control of the force-frequency and relaxationfrequency relations in patients with hypertrophic cardiomyopathy. Circulation 96: 2959-2968, 1997.
28. Jorde UP, Vittorio TJ, Kasper ME, Arezzi E, Colombo PC, Goldsmith RL, Ahuja K, Tseng CH, Haas F, Hirsh DS. Chronotropic incompetence, beta-blockers, and functional capacity in advanced congestive heart failure: time to pace? Eur J Heart Fail 10: 96-101, 2008.
29. Kaludercic N, Takimoto E, Nagayama T, Feng N, Lai EW, Bedja D, Chen K, Gabrielson KL, Blakely RD, Shih JC, Pacak K, Kass DA, Di Lisa F, Paolocci N. Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload. Circ Res 106: 193-202, 2010.
30. Kato M, Kinugawa T, Omodani H, Osaki S, Ahmmed GU, Ogino K, Hisatome I, Miyakoda H, Thames MD. Responses of plasma norepinephrine and renin-angiotensin system to dynamic exercise in patients with congestive heart failure. J Card Fail 2: 103-110, 1996.
31. 3-adrenoceptor stimulation in the beating guinea pig heart. J Cardiovasc Pharmacol 35: 786-790, 2000.
32. Kitzman DW, Brubaker PH, Morgan TM, Stewart KP, Little WC. Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. Circ Heart Fail 3: 659-667, 2010.
33. Kociol RD. Circulation: Heart Failure editor's picks: most important articles in heart failure and therapeutics. Circ Heart Fail 5: e73-e78, 2012.
34. Ladage D, Schwinger RH, Brixius K. Cardio-selective beta-blocker: pharmacological evidence and their influence on exercise capacity. Cardiovasc Ther 31: 76-83, 2012.
35. Lenfant C. Report of the Task Force on Research in Heart Failure. Circulation 90: 1118-1123, 1994.
36. 2-adrenergic receptor. Proc Natl Acad Sci USA 90: 3665-3669, 1993.
37. Little WC, Kitzman DW, Cheng CP. Diastolic dysfunction as a cause of exercise intolerance. Heart Fail Rev 5: 301-306, 2000.
38. Little WC, Cheng CP. Effect of exercise on left ventricular-arterial coupling assessed in the pressure-volume plane. Am J Physiol Heart Circ Physiol 264: H1629-H1633, 1993.
39. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of betaadrenergic signaling in heart failure? Circ Res 93: 896-906, 2003.
40. Masutani S, Cheng HJ, Hyttila-Hopponen M, Levijoki J, Heikkila A, Vuorela A, Little WC, Cheng CP. Orally available levosimendan: dose-related positive inotropic and lusitropic effect in conscious, chronically-instrumented normal and heart failure dogs. J Pharmacol Exp Ther 325: 236-247, 2008.
41. Masutani S, Cheng HJ, Tachibana H, Little WC, Cheng CP. Levosimendan restores the positive force-frequency relation in heart failure. Am J Physiol Heart Circ Physiol 301: H488-H496, 2011.
42. Miyazaki S, Guth BD, Miura T, Indolfi C, Schulz R, Ross J, Jr. Changes of left ventricular diastolic function in exercising dogs without and with ischemia. Circulation 81: 1058-1070, 1990.
43. Mongillo M, Tocchetti CG, Terrin A, Lissandron V, Cheung YF, Dostmann WR, Pozzan T, Kass DA, Paolocci N, Houslay MD, Zaccolo M. Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res 98: 226-234, 2006.
44. 3-adrenoceptor antagonists in heart failure therapy. Cardiovasc Drug Rev 20: 19-26, 2002.
45. Moniotte S, Belge C, Sekkali B, Massion PB, Rozec B, Dessy C, Balligand JL. Sepsis is associated with an upregulation of functional beta3 adrenoceptors in the myocardium. Eur J Heart Fail 9: 1163-1171, 2007.
46. 3-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation 103: 1649-1655, 2001.
47. Morimoto A, Hasegawa H, Cheng HJ, Little WC, Cheng CP. Endogenous beta3-adrenoreceptor activation contributes to left ventricular and cardiomyocyte dysfunction in heart failure. Am J Physiol Heart Circ Physiol 286: H2425-H2433, 2004.
48. Narang R, Swedberg K, Cleland JGF. What is the ideal study design for evaluation of treatment for heart failure? Eur Heart J 17: 120-134, 1996.
49. Nonogi H, Hess OM, Ritter M, Krayenbuehl HP. Diastolic properties of the normal left ventricle during supine exercise. Br Heart J 60: 30-38, 1988.
50. Nozawa T, Cheng CP, Noda T, Little WC. Effect of exercise on left ventricular mechanical efficiency in conscious dogs. Circulation 90: 3047-3054, 1994.
51. Ohte N, Cheng CP, Little WC. Tachycardia exacerbates abnormal left ventricular-arterial coupling in heart failure. Heart Vessels 18: 136-141, 2003.
52. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325: 1468-1475, 1991.
53. Papanicolaou DA, Petrides JS, Tsigos C, Bina S, Kalogeras KT, Wilder R, Gold PW, Deuster PA, Chrousos GP. Exercise stimulates interleukin-6 secretion: inhibition by glucocorticoids and correlation with catecholamines. Am J Physiol Endocrinol Metab 271: E601-E605, 1996.
54. Patrianakos AP, Parthenakis FI, Mavrakis HE, Diakakis GF, Chlouverakis GI, Vardas PE. Comparative efficacy of nebivolol versus carvedilol on left ventricular function and exercise capacity in patients with nonischemic dilated cardiomyopathy. A 12-month study. Am Heart J 150: 985. e9-985. e18, 2005.
55. Pelat M, Verwaerde P, Galitzky J, Lafontan M, Berlan M, Senard JM, Montastruc JL. High isoproterenol doses are required to activate beta3-adrenoceptor-mediated functions in dogs. J Pharmacol Exp Ther 304: 246-253, 2003.
56. Pina IL, Apstein CS, Balady GJ, Belardinelli R, Chaitman BR, Duscha BD, Fletcher BJ, Fleg JL, Myers JN, Sullivan MJ. Exercise and heart failure: a statement from the American Heart Association Committee on Exercise, Rehabilitation, and Prevention. Circulation 107: 1210-1225, 2003.
57. Ross J, Jr, Miura T, Kambayashi M, Eising GP, Ryu KH. Adrenergic control of force-frequency relation. Circulation 92: 2327-2332, 1995.
58. 3-adrenoceptors in the cardiovascular system: putative roles in human pathologies. Pharmacol Ther 111: 652-673, 2006.
59. 3-adrenoceptors among other beta-adrenoceptor subtypes in the regulation of the cardiovascular system. Arch Mal Coeur Vaiss 96: 905-913, 2003.
60. Senzaki H, Isoda T, Paolocci N, Ekelund U, Hare JM, Kass DA. Improved mechanoenergetics and cardiac rest and reserve function of in vivo failing heart by calcium sensitizer EMD-57033. Circulation 101: 1040-1048, 2000.
61. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, Hutchins S, Leier CV, LeJemtel TH, Loh E, Nicklas J, Ogilby D, Singh BN, Smith W. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 102: 2222-2227, 2000.
62. Tachibana H, Cheng HJ, Ukai T, Igawa A, Zhang ZS, Little WC, Cheng CP. Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure. Am J Physiol Heart Circ Physiol 288: H914-H922, 2005.
63. Trochu JN, Leblais V, Rautureau Y, Beverelli F, Le Marec H, Berdeaux A, Gauthier C. Beta3-adrenoceptor stimulation induces vasorelaxation mediated essentially by endothelium-derived nitric oxide in rat thoracic aorta. Br J Pharmacol 128: 69-76, 1999.
64. Ukai T, Cheng CP, Tachibana H, Igawa A, Zhang ZS, Cheng HJ, Little WC. Allopurinol enhances the contractile response to dobutamine and exercise in dogs with pacing-induced heart failure. Circulation 103: 750-755, 2001.
65. Yellin EL, Hori M, Yoran C, Sonnenblick EH, Gabbay S, Frater RW. Left ventricular relaxation in the filling and nonfilling intact canine heart. Am J Physiol Heart Circ Physiol 250: H620-H629, 1986.
66. 3-adrenoceptor expression in chronic heart failure. Cardiovasc Drugs Ther 21: 85-90, 2007.
67. 3-adrenoceptor deficiency. Pflügers Arch 453: 443-453, 2007.